We are monitoring the impact of COVID-19 on North America Parkinson’s Disease Treatment Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 7143
Share on
Share on

North America Parkinson’s Disease Treatment Market Research Report – Segmented By Drug Class, Distribution Channel, Patient Care Setting & Country (United States, Canada & Rest of North America) – Industry Size, Share, Trends, Growth & Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 7143
Pages: 145

The size of the North America Parkinson’s Disease Treatment Market was worth USD 1.14 billion in 2021 and estimated to be growing at a CAGR of 5.76%, to reach USD 1.51 billion by 2026.

The increasing prevalence of Parkinson’s disease in the region is leading to a rise in demand for an effective treatment, which eventually fuels the growth of the North America Parkinson’s disease treatment market. In North America, government authorities are increasing the funds to provide a better quality of healthcare to the people, which is boosting the growth of this market. The availability of skilled professionals in the region and diagnostic centers are also promoting the growth of the Parkinson’s disease treatment market in North America. 

Increasing patient pool in hospitals due to the availability of technologically advanced diagnostic laboratories is presumed to offer more growth opportunities for the market players over the forecast period. An increasing number of product launches in the region owing to the rise in the number of patients affected with Parkinson’s disease are likely to offer opportunities for the growth of the Parkinson’s disease treatment market in North America during the projection period. Increasing healthcare expenditure and rising investments in the healthcare of emerging countries such as Canada, Mexico, etc., are anticipated to create growth opportunities for Parkinson’s disease treatment market in North America.

The primary factor that is resisting the growth of the market is the availability of other treatment options to the patients. Stringent rules in approval procedures and high competition to the emerging players in the region are supposed to act as growth resisting factors of the North America Parkinson’s disease treatment market.

This research report on the North America Parkinson's Disease Treatment Market is segmented and sub-segmented into the following categories:

By Drug Class:

  • Dopamine Receptor Antagonists
    • Pramipexole
    • Ropinirole
    • Apomorphine
    • Rotigotine
  • Mono Amine Oxidase Inhibitors
    • Selegiline
    • Rasagiline
  • Carbidopa
  • Anticholinergics
  • Other Drug Classes

By Distribution Channels:

  • Retailer Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Patient Care Setting:

  • Clinics
  • Hospitals 

By Country:

  • the United States
  • Canada
  • Rest of North America

Regionally, North America has the second-largest market for Parkinson's disease treatment in the world by share. In the North America region, the United States has the largest share. Factors such as the growing geriatric population and increasing government funding for research are expected to drive the market growth in the region.  

Some of the major players in the North America Parkinson’s Disease Treatment Market are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Class                   

                                5.1.1 Dopamine Receptor Antagonists   

                                                5.1.1.1 Pramipexole

                                                5.1.1.2 Ropinirole

                                                5.1.1.3 Apomorphine

                                                5.1.1.4 Rotigotine

                                5.1.2 Mono Amine Oxidase Inhibitors    

                                                5.1.2.1 Selegiline

                                                5.1.2.2 Rasagiline

                                5.1.3 Carbidopa

                                5.1.4 Anticholinergics    

                                5.1.5 Other Drug Classes              

                                5.1.6  Y-o-Y Growth Analysis, By Drug Class          

                                5.1.7  Market Attractiveness Analysis, By Drug Class        

                                5.1.8  Market Share Analysis, By Drug Class         

                5.2 Distribution Channel                               

                                5.2.1 Retailer Pharmacies            

                                5.2.2 Hospital Pharmacies            

                                5.2.3 Online Pharmacies               

                                5.2.4 Y-o-Y Growth Analysis, By Distribution Channel      

                                5.2.5 Market Attractiveness Analysis, By Distribution Channel    

                                5.2.6 Market Share Analysis, By Distribution Channel      

                5.3 Patient Care Setting                

                                5.3.1 Clinics        

                                5.3.2 Hospitals  

                                5.3.3 Y-o-Y Growth Analysis, By Patient Care Setting       

                                5.3.4  Market Attractiveness Analysis, By Patient Care Setting    

                                5.3.5  Market Share Analysis, By Patient Care Setting      

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Drug Class

                                                6.1.3.2 By Distribution Channel

                                                6.1.3.3 By Patient Care Setting

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Drug Class

                                                6.1.4.2 By Distribution Channel

                                                6.1.4.3 By Patient Care Setting

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Drug Class

                                                6.1.5.2 By Distribution Channel

                                                6.1.5.3 By Patient Care Setting

                6.2 United States                            

                6.3 Canada                         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Teva                              

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis AG                                

                8.3 GSK                                

                8.4 AbbVie                         

                8.5 Merck                           

                8.6 Boehringer Ingelheim                            

                8.7 Impax Laboratories                 

                8.8 Lundbeck                    

                8.9 Sun Pharma                                

                8.10 Wockhardt                               

                8.11 UCB                             

                8.12 Valeant Pharmaceuticals                    

                8.13 Acadia                        

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms By Drug Class and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Parkinson’s Disease Treatment Market By Drug Class , From 2021 to 2026 ( USD Billion )
    North America Dopamine Receptor Antagonists Market By Region, From 2021 to 2026 ( USD Billion )
    North America Mono Amine Oxidase Inhibitors Market By Region, From 2021 to 2026 ( USD Billion )
    North America Carbidopa Market By Region, From 2021 to 2026 ( USD Billion )
    North America Anticholinergics  Market By Region, From 2021 to 2026 ( USD Billion )
    North America Other Drug Classes Market By Region, From 2021 to 2026 ( USD Billion )
    North America Parkinson’s Disease Treatment Market By Distribution Channel , From 2021 to 2026 ( USD Billion )
    North America Retailer Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
    North America Hospital Pharmacies  Market By Region, From 2021 to 2026 ( USD Billion )
    North America Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
    North America Parkinson’s Disease Treatment Market By Patient Care Setting, From 2021 to 2026 ( USD Billion )
    North America Clinics  Market By Region, From 2021 to 2026 ( USD Billion )
    North America Hospitals Market By Region, From 2021 to 2026 ( USD Billion )
    United States Parkinson’s Disease Treatment Market By Drug Class , From 2021 to 2026 ( USD Billion )
    United States Parkinson’s Disease Treatment Market By Distribution Channel , From 2021 to 2026 ( USD Billion )
    United States Parkinson’s Disease Treatment Market By Patient Care Setting, From 2021 to 2026 ( USD Billion )
    Canada Parkinson’s Disease Treatment Market By Drug Class , From 2021 to 2026 ( USD Billion )
    Canada Parkinson’s Disease Treatment Market By Distribution Channel , From 2021 to 2026 ( USD Billion )
    Canada Parkinson’s Disease Treatment Market By Patient Care Setting, From 2021 to 2026 ( USD Billion )
    North America Parkinson’s Disease Treatment Market By Drug Class , From 2021 to 2026 ( USD Billion )
    North America Dopamine Receptor Antagonists Market By Region, From 2021 to 2026 ( USD Billion )
    North America Mono Amine Oxidase Inhibitors Market By Region, From 2021 to 2026 ( USD Billion )
    North America Carbidopa Market By Region, From 2021 to 2026 ( USD Billion )
    North America Anticholinergics  Market By Region, From 2021 to 2026 ( USD Billion )
    North America Other Drug Classes Market By Region, From 2021 to 2026 ( USD Billion )
    North America Parkinson’s Disease Treatment Market By Distribution Channel , From 2021 to 2026 ( USD Billion )
    North America Retailer Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
    North America Hospital Pharmacies  Market By Region, From 2021 to 2026 ( USD Billion )
    North America Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
    North America Parkinson’s Disease Treatment Market By Patient Care Setting, From 2021 to 2026 ( USD Billion )
    North America Clinics  Market By Region, From 2021 to 2026 ( USD Billion )
    North America Hospitals Market By Region, From 2021 to 2026 ( USD Billion )
    United States Parkinson’s Disease Treatment Market By Drug Class , From 2021 to 2026 ( USD Billion )
    United States Parkinson’s Disease Treatment Market By Distribution Channel , From 2021 to 2026 ( USD Billion )
    United States Parkinson’s Disease Treatment Market By Patient Care Setting, From 2021 to 2026 ( USD Billion )
    Canada Parkinson’s Disease Treatment Market By Drug Class , From 2021 to 2026 ( USD Billion )
    Canada Parkinson’s Disease Treatment Market By Distribution Channel , From 2021 to 2026 ( USD Billion )
    Canada Parkinson’s Disease Treatment Market By Patient Care Setting, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample